绝经后妇女骨质疏松症的管理:北美绝经学会 2010 年立场声明。
Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
出版信息
Menopause. 2010 Jan-Feb;17(1):25-54; quiz 55-6. doi: 10.1097/gme.0b013e3181c617e6.
OBJECTIVE
To update the evidence-based position statement published by The North American Menopause Society (NAMS) in 2006 regarding the management of osteoporosis in postmenopausal women.
METHODS
NAMS followed the general principles established for evidence-based guidelines to create this updated document. A panel of clinicians and researchers expert in the field of metabolic bone diseases and/or women's health was enlisted to review the 2006 NAMS position statement, compile supporting statements, and reach consensus on recommendations. The panel's recommendations were reviewed and approved by the NAMS Board of Trustees.
RESULTS
Osteoporosis, which is especially prevalent among older postmenopausal women, increases the risk of fractures. Hip and spine fractures are associated with particularly high morbidity and mortality in this population. Given the health implications of osteoporotic fractures, the primary goal of osteoporosis therapy is to prevent fractures, which is accomplished by slowing or stopping bone loss, maintaining bone strength, and minimizing or eliminating factors that may contribute to fractures. The evaluation of postmenopausal women for osteoporosis risk requires a medical history, physical examination, and diagnostic tests. Major risk factors for postmenopausal osteoporosis (as defined by bone mineral density) include advanced age, genetics, lifestyle factors (such as low calcium and vitamin D intake, smoking), thinness, and menopause status. The most common risk factors for osteoporotic fracture are advanced age, low bone mineral density, and previous fracture as an adult. Management focuses first on nonpharmacologic measures, such as a balanced diet, adequate calcium and vitamin D intake, adequate exercise, smoking cessation, avoidance of excessive alcohol intake, and fall prevention. If pharmacologic therapy is indicated, government-approved options are bisphosphonates, selective estrogen-receptor modulators, parathyroid hormone, estrogens, and calcitonin.
CONCLUSIONS
Management strategies for postmenopausal women involve identifying those at risk for fracture, followed by instituting measures that focus on reducing modifiable risk factors through dietary and lifestyle changes and, if indicated, pharmacologic therapy.
目的
更新北美绝经学会(NAMS)2006 年发布的关于绝经后妇女骨质疏松症管理的循证立场声明。
方法
NAMS 遵循为循证指南制定的一般原则来创建这份更新文件。一个由代谢性骨疾病和/或妇女健康领域的临床医生和研究人员组成的专家小组被招募来审查 2006 年 NAMS 立场声明,编制支持性声明,并就建议达成共识。小组的建议由 NAMS 董事会审查和批准。
结果
骨质疏松症在老年绝经后妇女中尤为普遍,会增加骨折的风险。髋部和脊柱骨折与该人群的高发病率和死亡率特别相关。鉴于骨质疏松性骨折的健康影响,骨质疏松症治疗的主要目标是预防骨折,这可以通过减缓或停止骨质流失、保持骨强度以及最小化或消除可能导致骨折的因素来实现。对绝经后妇女进行骨质疏松症风险评估需要进行病史、体格检查和诊断性检查。绝经后骨质疏松症(根据骨密度定义)的主要危险因素包括年龄较大、遗传因素、生活方式因素(如钙和维生素 D 摄入不足、吸烟)、消瘦和绝经状态。骨质疏松性骨折最常见的危险因素是年龄较大、骨密度较低和成年后骨折。管理首先侧重于非药物措施,如均衡饮食、充足的钙和维生素 D 摄入、适量运动、戒烟、避免过度饮酒和预防跌倒。如果需要药物治疗,则可选择政府批准的药物,如双膦酸盐、选择性雌激素受体调节剂、甲状旁腺激素、雌激素和降钙素。
结论
绝经后妇女的管理策略包括确定骨折风险高的患者,然后通过饮食和生活方式改变来减少可改变的危险因素,如果需要,则进行药物治疗。